Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이준호 | - |
dc.contributor.author | 정성현 | - |
dc.contributor.author | 김석진 | - |
dc.contributor.author | 윤덕현 | - |
dc.contributor.author | 강혜진 | - |
dc.contributor.author | 고영일 | - |
dc.contributor.author | 김진석 | - |
dc.contributor.author | 이원식 | - |
dc.contributor.author | 양덕환 | - |
dc.contributor.author | 도영록 | - |
dc.contributor.author | 김민경 | - |
dc.contributor.author | 유쾌한 | - |
dc.contributor.author | 최윤석 | - |
dc.contributor.author | 윤환정 | - |
dc.contributor.author | 박용 | - |
dc.contributor.author | 조재철 | - |
dc.contributor.author | 엄현석 | - |
dc.contributor.author | 곽재용 | - |
dc.contributor.author | 신호진 | - |
dc.contributor.author | 박병배 | - |
dc.contributor.author | 이성윤 | - |
dc.contributor.author | 권지현 | - |
dc.contributor.author | 오성용 | - |
dc.contributor.author | 김효정 | - |
dc.contributor.author | 손병석 | - |
dc.contributor.author | 원종호 | - |
dc.contributor.author | 홍대식 | - |
dc.contributor.author | 이호섭 | - |
dc.contributor.author | 이경원 | - |
dc.contributor.author | 서철원 | - |
dc.contributor.author | 김원석 | - |
dc.date.accessioned | 2023-11-07T04:44:48Z | - |
dc.date.available | 2023-11-07T04:44:48Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.issn | 2005-9256 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/68490 | - |
dc.description.abstract | Purpose Diffuse large B-cell lymphoma (DLBCL) is the most common hematologic malignancy worldwide. Although substantial improvement has been achieved by the frontline rituximab-based chemoimmunotherapy, up to 40%-50% of patients will eventually have relapsed or refractory disease, whose prognosis is extremely dismal.Materials and Methods We have carried out two prospective cohort studies that include over 1,500 DLBCL patients treated with rituximab plus CHOP (#NCT01202448 and #NCT02474550). In the current report, we describe the outcomes of refractory DLBCL patients. Patients were defined to have refractory DLBCL if they met one of the followings, not achieving at least partial response after 4 or more cycles of R-CHOP; not achieving at least partial response after 2 or more cycles of salvage therapy; progressive disease within 12 months after autologous stem cell transplantation.Results Among 1,581 patients, a total of 260 patients met the criteria for the refractory disease after a median time to progression of 9.1 months. The objective response rate of salvage treatment was 26.4%, and the complete response rate was 9.6%. The median overall survival (OS) was 7.5 months (95% confidence interval, 6.4 to 8.6), and the 2-year survival rate was 22.1%±2.8%. The median OS for each refractory category was not significantly different (p=0.529).Conclusion In line with the previous studies, the outcomes of refractory DLBCL patients were extremely poor, which necessitates novel approaches for this population. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한암학회 | - |
dc.title | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | - |
dc.title.alternative | Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts | - |
dc.type | Article | - |
dc.identifier.doi | 10.4143/crt.2022.008 | - |
dc.identifier.bibliographicCitation | Cancer Research and Treatment, v.55, no.1, pp 325 - 333 | - |
dc.identifier.kciid | ART002923414 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000957087400029 | - |
dc.identifier.scopusid | 2-s2.0-85133198199 | - |
dc.citation.endPage | 333 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 325 | - |
dc.citation.title | Cancer Research and Treatment | - |
dc.citation.volume | 55 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Diffuse large B-cell lymphoma | - |
dc.subject.keywordAuthor | Refractory | - |
dc.subject.keywordAuthor | Clinical outcomes | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | R-CHOP | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | FAILURE | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.